



# Herpes Zoster and COVID-19 Vaccination: A Narrative Review

Luca Potestio , Matteo Megna, Alessia Villani, Sara Cacciapuoti, Massimiliano Scalvenzi, Fabrizio Martora 

Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy

Correspondence: Luca Potestio, Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, Napoli, 80131, Italy, Tel +39 - 081 - 7462457, Fax +39 - 081 - 7462442, Email potestioluca@gmail.com

**Abstract:** COVID-19 was a worldwide emergency, leading to a global health crisis, which completely revolutionized every aspect of human life. Several strategies were adopted to limit the spreading of the infection such as testing and contact tracing, quarantine and isolation, use of face mask, social distancing, lockdowns, travel restrictions, etc. Of these, vaccines were the most important measures to reduce the transmission of the virus and the severity of the infection, in order to overcome the pandemic. Fortunately, vaccination campaign was a success, showing to be efficient in controlling and preventing the COVID-19, reducing the risk of disease progression, hospitalization, and mortality. Monitoring and addressing vaccine-related adverse events have been essential for maintaining public confidence. Indeed, with the increasing number of vaccines administered, various cutaneous reactions have been reported, making dermatologists key players in their recognition and treatment. Particularly, several cutaneous diseases and cutaneous findings have been reported. Of note, also viral reactivations have been described following COVID-19 vaccination. Among these, varicella zoster virus (VZV) reactivation has been collected. Globally, an early diagnosis and an accurate treatment of herpes zoster (HZ) is mandatory to reduce possible complications. In this context, we conducted a review of the current literature investigating cases HZ following COVID-19 vaccination with the aim of understanding the possible causal correlation and underlying pathogenetic mechanisms to offer clinicians a wide perspective on VZV reactivation and COVID-19 vaccines.

**Keywords:** COVID-19, vaccination, herpes zoster, safety

## Introduction

In late 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as coronavirus disease 2019 (COVID-19), started to spread around the world, becoming a worldwide emergency and leading to a global health crisis, which completely revolutionized every aspect of human life.<sup>1-3</sup> Several strategies were adopted to limit the spreading of the infection such as testing and contact tracing, quarantine and isolation, use of face mask, social distancing, lockdowns, travel restrictions, public health messages, hygiene measures, international cooperation, and vaccination campaign.<sup>4-6</sup>

Of these, vaccines were the most important measures to reduce the transmission of the virus and the severity of the infection, in order to overcome the pandemic.<sup>7</sup> Currently, 4 vaccines have been licensed by the European Medicines Agency (EMA), with two different mechanisms of action: viral-vector-based vaccines (AstraZeneca; AZD1222 and Johnson & Johnson; Ad26.COV2.) and mRNA-based vaccines (Pfizer/BioNTech; BNT162b2 and Moderna; mRNA-1273).<sup>7</sup> Moreover, several vaccines have been authorized in other countries such as “Sputnik V” (Gamaleya Research Institute), “Convidecia” (CanSino Biologics), and “CoronaVac” (Sinovac).<sup>7</sup> However, also vaccination campaign was a global challenge due to several concerns raised by vaccines themselves.<sup>8-10</sup> First of all, there were logistic concerns (vaccine supply and distribution, production capacity, equitable access, infrastructure and healthcare workforce, logistical challenges, public communication, legal and regulatory challenges, etc.).<sup>8,9</sup> Secondly, vaccination campaign was also limited by vaccine hesitancy, often due to misinformation and mistrust of vaccination related to the rapidity of production

of vaccines and the mechanism of action, particularly mRNA based.<sup>8,9</sup> Fortunately, the initial doubts about vaccines were overcome as well as logistic concerns were solved.<sup>8,9,11</sup> On consequence, vaccination campaign was a success, showing to be efficient in controlling and preventing the COVID-19 pandemic, reducing the risk of disease progression, hospitalization, and mortality.<sup>8,9</sup>

In this scenario, monitoring and addressing vaccine-related adverse events (AEs) have been essential for maintaining public confidence.<sup>12,13</sup> As regards the dermatological field, with the increasing number of vaccines administered, various cutaneous reactions have been reported, making dermatologists key players in their recognition and treatment.<sup>14–20</sup> Particularly, several cutaneous diseases (eg, psoriasis, lichen planus, hidradenitis suppurativa, bullous diseases, etc.) and cutaneous findings (eg, maculopapular, urticarial, vesicular rashes, etc.) have been reported.<sup>21–23</sup> However, the clinical significance of these reactions, and the possible pathogenetic mechanisms, is still unknown, as well as it should be noted that in the majority of cases, these reactions were self-resolving or limited to a few days.<sup>21–23</sup> Of note, also viral reactivations have been described following COVID-19 vaccination. Among these, varicella zoster virus (VZV) reactivation has been collected. VZV is a complex medical condition that may involve infectiology, dermatology, and neurology, making its treatment challenging.<sup>24–26</sup> While varicella is caused by acute viremia, herpes zoster (HZ) is caused by viral reactivation, typically involving a single dermatome and presenting as burning or pain followed by a cutaneous eruption with multiple umbilicated and painful vesicles.<sup>27</sup> The exact triggers for reactivation are not fully understood but may involve a weakened immune system, aging, or stress.<sup>27</sup> Moreover, HZ infection may be complicated by postherpetic neuralgia, secondary bacterial infection, or ophthalmic complications.<sup>27</sup> Thus, an early diagnosis and an accurate treatment are mandatory.<sup>27</sup> In this context, we conducted a review of the current literature investigating cases HZ following COVID-19 vaccination with the aim of understanding the possible causal correlation and underlying pathogenetic mechanisms to offer clinicians a wide perspective on VZV reactivation and COVID-19 vaccines.

## Materials and Methods

For this review manuscript, a comprehensive literature search was performed by using several databases (Embase, MEDLINE, EBSCO, PubMed, Google Scholar, and the Cochrane Skin), up until September 19, 2023. The following terms were searched and matched to find relevant manuscripts: “COVID-19”, “SARS-Coronavirus-2”, “SARS-CoV-2”; “cutaneous disease”, “cutaneous reactions”, “adverse events”, “BNT162b2”, “side effects”, “mRNA”, “AZD1222”, “viral-vector”, “mRNA-1273”, “Johnson & Johnson”, “Pfizer/BioNTech”, “Moderna”, “Ad26.COV2.S”, “AstraZeneca”, “vaccine”, “vaccination”, “efficacy”, “safety”, “herpes zoster”. The Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) guidelines were followed to point out relevant data from the screened and analyzed articles.<sup>28</sup> Moreover, only English language manuscripts were considered. Furthermore, the abstracts and the texts of designated articles were reviewed to refine the research as well as references were also considered to avoid that some manuscripts could be missed. Exclusion criteria include: non-English manuscripts, article regarding other viral reactivations or non-involving vaccines approved by EMA. This manuscript is based on previously performed studies and does not contain any studies with human or animals participants carried out by any of the authors.

## Results

A total of 76 records were found from the investigated databases. However, only 72 manuscripts were assessed for eligibility, since duplicate manuscripts and articles non-respecting study were excluded. Finally, 31 manuscripts were selected at the end of the literature research for our review.<sup>29–60</sup>

The results have been summarized in Table 1.

Globally, 4555 cases of HZ following COVID-19 vaccinations were found. Among these, the largest number of cases has been reported by Florea et al in a cohort study investigating the association between mRNA COVID-19 vaccination and subsequent HZ development within 90 days from vaccination.<sup>29</sup> Cohort included: mRNA-1273 recipients (n = 1.052.362), BNT162b2 recipients (n = 1.055.461), and comparators (n = 1.020.334).<sup>29</sup> The authors showed and adjusted hazard ratio (aHR) for HZ up to 90 days following the second dose of mRNA-1273 and BNT162b2 of 1.14 (1.05–1.24) and 1.12 (1.03–1.22), respectively.<sup>29</sup> Moreover, an aHR of 1.18 (1.06–1.33) and 1.15 (1.02–1.29) was found in patients aged  $\geq 50$  years after the second dose of mRNA-1273 and BNT162b2 vaccine as compared with unvaccinated subjects.<sup>29</sup>

**Table I** Varicella Zoster Virus Reactivation After COVID-19 Vaccine

Authors	Country	Cases	Vaccines	Time	Dose
Florea et al <sup>29</sup>	US	2797	BNT162b2: 1313 mRNA-1273: 1484	Maximum 90 days	First dose: 0 Second dose: 2797
Birabakaran et al <sup>41</sup>	US	1228	BNT162b2: NR mRNA-1273: NR	Maximum 28 days	NR
Barda et al <sup>30</sup>	US	283	BNT162b2: 283	Maximum 42 days	NR
Akpandak et al <sup>52</sup>	US	45	BNT162b2: NR mRNA-1273: NR Ad26.CO2: NR	Medium: 12 days	NR
Català et al <sup>55</sup>	Spain	41	BNT162b2: 28 mRNA-1273: 6 AZD1222:7	Medium: 4.6 days	NR
Fathy et al <sup>56</sup>	US	35	BNT162b2: 19 mRNA-1273: 16	Medium: 7 days	First dose: 27 Second dose: 18
Naoum et al <sup>57</sup>	German	22	BNT162b2: 16 mRNA-1273: 5 AZD1222:1	Medium: 10 days	First dose: 13 Second dose: 9
Lee et al <sup>58</sup>	US	20	BNT162b2: 6 mRNA-1273: 14	Medium: 3–38 days	First dose: 15 Second dose: 5
Lee et al <sup>59</sup>	Korea	14	BNT162b2: 5 mRNA-1273: 5 AZD1222: 4	Days 1–21: 9 Days 22–42: 5	First dose: 4 Second dose: 10
McMahon et al <sup>60</sup>	US	10	BNT162b2: 5 mRNA-1273: 5	Medium: 7 days	First dose: 6 Second dose: 4
Monastirli et al <sup>31</sup>	Greece	7	BNT162b2: 7	NR	First dose: 4 Second dose: 3
Psichogiou et al <sup>32</sup>	Greece	7	BNT162b2: 7	Medium: 9 days	First dose: 5 Second dose: 2
Furer et al <sup>33</sup>	Israel	6	BNT162b2: 6	Medium: 3–14 days	First dose: 5 Second dose: 1
Rodríguez-Jiménez et al <sup>34</sup>	Spain	5	BNT162b2: 5	Medium: 1–16 days	First dose: 5 Second dose: 0
Alpalhão et al <sup>35</sup>	Portugal	4	BNT162b2: 2 AZD1222:2	Medium: 3–6 days	First dose: 4 Second dose: 0
Chiu et al <sup>36</sup>	Taiwan	3	mRNA-1273: 1 AZD1222:2	Medium: 2–7 days	First dose: 3 Second dose: 0
Jiang et al <sup>37</sup>	Taiwan	3	AZD1222: 3	Medium: 3–7 days	NR
Lazzaro et al <sup>38</sup>	US	3	BNT162b2: 3	Maximum: 14 days	First dose: 3 Second dose: 0
Mohta et al <sup>39</sup>	India	3	AZD1222: 3	Maximum: 7 days	First dose: 3 Second dose: 0

(Continued)

**Table 1** (Continued).

Authors	Country	Cases	Vaccines	Time	Dose
Vastarella et al <sup>40</sup>	Italy	3	AZD1222:3	Medium: 6–10 days	First dose: 3 Second dose: 0
Özdemir et al <sup>42</sup>	Turkey	2	AZD1222: 2	Medium: 1–2 days	First dose: 2 Second dose: 0
Palanivel <sup>43</sup>	India	2	AZD1222:2	Medium: 4–7 days	First dose: 2 Second dose: 0
Rehman et al <sup>44</sup>	India	2	AZD1222: 2	Medium: 3–28 days	NR
Toscani et al <sup>45</sup>	Italy	2	BNT162b2: 2	Medium: 2–24 days	First dose: 0 Second dose: 2
Aksu et al <sup>46</sup>	Turkey	1	BNT162b2: 1	Medium: 5 days	First dose: 0 Second dose: 1
Ardalan et al <sup>47</sup>	Iran	1	AZD1222:1	Medium: 2 days	First dose: 1 Second dose: 0
Channa et al <sup>48</sup>	US	1	mRNA-1273: 1	Medium: 3 days	First dose: 0 Second dose: 1
David et al <sup>49</sup>	US	1	mRNA-1273: 1	Medium: 8 days	First dose: 1 Second dose: 0
Tessas et al <sup>50</sup>	Finland	1	BNT162b2: 1	Medium: 7 days	First dose: 1 Second dose: 0
Tripathy et al <sup>51</sup>	India	1	AZD1222: 1	Medium: 5 days	First dose: 1 Second dose: 0
Vallianou et al <sup>53</sup>	Greece	1	BNT162b2: 1	Medium: 11 days	First dose: 1 Second dose: 0
You et al <sup>54</sup>	Korea	1	BNT162b2: 1	Medium: 5 days	NR

In conclusion, the authors suggested an increased risk of HZ following COVID-19 vaccination, especially in patients aged  $\geq 50$  years without history of zoster vaccination.<sup>29</sup>

Similarly, Barda et al assessed an increased risk of VZV reactivation following COVID-19 vaccination with BNT162b2 in their cohort study involving 884,828 subjects.<sup>30</sup> Among these, 283 cases of HZ were collected, suggesting a positive correlation between VZV reactivation and vaccination (risk ratio, 1.43; 95% CI, 1.20 to 1.73; risk difference, 15.8 events per 100,000 persons; 95% CI, 8.2 to 24.2).<sup>30</sup>

On the contrary, Birabaharan et al reported the results a cohort study enrolling 1,306,434 patients receiving at least one dose of mRNA-based COVID-19 vaccine.<sup>41</sup> Of these, 1,228 (0.1%) reported VZV reactivation within maximum of 28 days after vaccine. Nevertheless, a statistically significant association between HZ and COVID-19 vaccination was not found.<sup>41</sup> On consequence, the authors stated that COVID-19 vaccination was not associated with an increased risk of HZ.<sup>41</sup> The main limitation of the study was the absence of the specification of the dose and type of mRNA vaccine.<sup>41</sup> In line with Birabaharan et al, also Akpandak et al showed that there was not an increased risk of VZV following COVID-19 vaccination in their cohort of 1,959,157 individuals.<sup>52</sup> Indeed, only 45 cases were reported, allowing the authors to conclude that there was not an increased risk of HZ following vaccination with BNT162b2 (IRR = 0.90, 95% CI: 0.49–1.69,  $p = 0.74$ ), mRNA-1273 (IRR = 0.74, 95% CI: 0.36–1.54,  $p = 0.42$ ), or Ad26.COV2.S (IRR = 0.50, 95% CI: 0.07–2.56,  $p = 0.42$ ).<sup>52</sup>

Globally, the remaining cases of HZ development following COVID-19 vaccination were limited to case series and case reports. Among these, it should be pointed out 6 cases of HZ in patients with autoimmune inflammatory rheumatic diseases,<sup>31</sup> 3 subjects with VZV meningitis complicated by enhancing nodular leptomeningeal lesions of the spinal cord and VZV ophthalmicus of the cornea and eyelid, respectively,<sup>38</sup> and a case of VZV reactivation in a patient previously vaccinated for VZV.<sup>53</sup>

Globally, the type of COVID-19 vaccination associated with HZ development was described only for 3282 out of 4555 subjects (72.1%), with BNT162b2 as the commonest ( $n = 1711$ ), followed by mRNA-1273 ( $n = 1538$ ), and Ad26.COV2 ( $n = 33$ ). Finally, the time between vaccination and VZV development ranged from 1 to 90 days.

## Discussion

COVID-19 pandemic period strongly affected daily routine. Dermatological clinical practice was strongly forced to adopt strategies to contrast the COVID-19 diffusion in order to allow patients the continuity of care.<sup>61–64</sup> As regards the dermatological practice, dermatologists played a key role during the pandemic making possible to allow the continuity of care for patients affected by chronic disorders requiring various treatment such as biologics,<sup>65–71</sup> as well as the management of skin cancers.<sup>72–74</sup>

Globally, among the several measures adopted to contain COVID-19 infection,<sup>75</sup> vaccination was the most important. The Herpesviridae family is a large family of double-stranded DNA viruses that infect a wide range of animals, including humans, characterized by their ability to establish latent infections, which means they can remain dormant in the host's cells for extended periods and reactivate later.<sup>76–78</sup> Three subfamilies can be distinguished: alphaherpesvirinae (herpes simplex virus type 1 and herpes simplex virus type 2, which cause oral and genital herpes, as well as varicella-zoster virus), betaherpesvirinae (cytomegalovirus, human herpesvirus 6, and human herpesvirus 7 (HHV-7)), gammaherpesvirinae (Epstein–Barr virus and Kaposi's sarcoma-associated herpesvirus). In particular, alphaherpesvirinae establishes latent infections in neurons, while betaherpesvirinae and gammaherpesvirinae establish latent infections in the immune system and in lymphocytes and epithelial cells, respectively.<sup>76–78</sup> These viruses can cause a wide range of diseases, from mild cold sores to severe and potentially life-threatening conditions, depending on the specific virus and the host's immune status.<sup>76–78</sup> Reactivation of herpesviruses (Epstein–Barr virus, cytomegalovirus and herpes simplex virus) following COVID-19 vaccination have been reported by several case reports. However, VZV reactivation is the commonest. In this context, we performed a review of the current literature to determine the correlation between the COVID-19 vaccination and VZV. Of interest, VZV reactivation was also reported following COVID-19 infection.<sup>79</sup>

In our review, a total of 31 manuscripts were collected, reporting 4555 cases of HZ development following COVID-19 vaccination. In particular, BNT162b2 was reported as the commonest type of vaccine associated with VZV reactivation, followed by mRNA-1273 and Ad26.COV2. However, it should be stated that BNT162b2 is the commonest type of vaccine administered. Finally, the time between vaccination and VZV development ranged from 1 to 90 days. Of interest, cases of HZ have been described following both doses of vaccinations as well as both types of mechanism of action (mRNA-based or viral-vector based) suggesting that the possible pathogenetic mechanisms are independent from the mechanism of action of vaccine. Globally, age, weakened immune system, stress, certain medical conditions, injury or trauma, are considered as possible risk factors. In theory, these conditions may lead to the reactivation of VZV.<sup>80–85</sup> As regards COVID-19 vaccination and HZ, the possible pathogenetic mechanism may be found in the immune imbalance related to the vaccination.<sup>80–85</sup> Indeed, vaccine causes CD8<sup>+</sup> T cells reduction, increased NF- $\kappa$ B signaling, increase in classic monocyte contents, and reduced type I interferon responses, leading the immune system in a vulnerable state.<sup>80–85</sup> In particular, type I IFN receptor signaling in CD8<sup>+</sup> T cells plays an essential role in regulating memory cell response to viral infection and blockage of reactivation.<sup>80–85</sup> On consequence, the alteration of this system related to COVID-19 vaccination may be the cause of VZV reactivation.<sup>80–85</sup> To summarize, cases of VZV reactivation have been reported also following other vaccines (such as influenza, diphtheria, tuberculosis, poliomyelitis, etc.).<sup>80–86</sup> It is possible that in predisposed individuals, immune dysregulations induced by vaccines may lead to viral reactivation, similar to the phenomenon of “immune reconstitution inflammatory syndrome” observed during HIV treatment.<sup>80–85</sup> The stimulation of the immune response and its polarization towards a specific T-cell response against a particular infectious agent (eg, a vaccine) may temporarily compromise the T-cell-mediated control of latent infections like VZV, HSV, HHV-6, and HHV-7, leading to viral reactivation.<sup>80–85</sup> However, the exact pathogenetic mechanism remains unknown and further studies are needed.

Moreover, it should be stated that cases of HZ following vaccination are rare, and only few complicated cases have been described, as well as the safety of vaccination has been reported also in patients undergoing biologics.<sup>87–90</sup> Thus,

more studies are needed to identify possible risk factors, which may increase the risk of VZV following COVID-19 vaccination as well as the protective role of VZV vaccine in order to identify “at-risk” patients. Certainly, the possibility of HZ following vaccination should be considered in order to early recognize and treat this disease.

## Strengths and Limitations

The main strengths of our work were the PRISMA methods for the literature research and the number and quality of investigated articles. Indeed, our study offers a comprehensive overview of the published literature and highlights the available data with rigorous quality assessment.

Limitations of the study should also be discussed. First of all, despite all of the reported cases that have been collected in our review, the number of patients is inadequate for certainly assessing the correlation between vaccines and VZV reactivation. Second, clinical trials or comparison between vaccinated and non-vaccinated participants are lacking. Furthermore, the causal temporal correlation between COVID-19 vaccination and viral reaction cannot be ruled out in most of the cases. In addition, several viral reactivations related to COVID-19 vaccines have not been described in literature because they were mild and/or patients did not seek medical advice, leading to an underestimation of the epidemiological value of our work. Moreover, our assumptions, especially in the discussion, must be taken simply as suggestions and not as definite proposals, as our work has not had the support of meta-analysis, which may allow our results to be generalized. Finally, several cutaneous reactions related to COVID-19 vaccination were not considered in our review.<sup>91,92</sup>

## Conclusions

COVID-19 vaccination campaign was a worldwide success. However, with the raising number of vaccinated individuals, several cutaneous reactions have been reported, which often were not collected in clinical trials. Among these, viral reactivations have been described. In our review, we focused the attention to VZV reactivation following COVID-19 vaccination, which is the commonest described viral reactivation. Fortunately, the percentage of HZ development is extremely low if compared with the number of vaccines administered as well as an increased risk of VZV reactivation following vaccination cannot be statistically demonstrated. In our opinion, clinicians should keep in mind the possibility of HZ development following vaccination to offer patients a personalized approach.<sup>93,94</sup> Moreover, more studies are needed to identify “at-risk” patients and adopt preventative measures. Certainly, vaccines should not be discouraged.

## Disclosure

The authors report no conflicts of interest in this work.

## References

1. Sharma A, Ahmad Farouk I, Lal SK. COVID-19: a review on the novel coronavirus disease evolution, transmission, detection, control and prevention. *Viruses*. 2021;13(2):202. doi:10.3390/v13020202
2. Hadj Hassine I. Covid-19 vaccines and variants of concern: a review. *Rev Med Virol*. 2022;32(4):e2313. doi:10.1002/rmv.2313
3. Smith DRM, Chervet S, Pinettes T, et al. How have mathematical models contributed to understanding the transmission and control of SARS-CoV-2 in healthcare settings? A systematic search and review. *J Hosp Infect*. 2023;141:132–141. doi:10.1016/j.jhin.2023.07.028
4. Salian VS, Wright JA, Vedell PT, et al. COVID-19 transmission, current treatment, and future therapeutic strategies. *Mol Pharm*. 2021;18(3):754–771. doi:10.1021/acs.molpharmaceut.0c00608
5. Khan M, Adil SF, Alkhathlan HZ, et al. COVID-19: a global challenge with old history, epidemiology and progress so far. *Molecules*. 2020;26(1):39. doi:10.3390/molecules26010039
6. Ruggiero A, Martora F, Fabbrocini G, et al. The role of teledermatology during the COVID-19 pandemic: a narrative review. *Clin Cosmet Investig Dermatol*. 2022;15:2785–2793. doi:10.2147/CCID.S377029
7. Rashedi R, Samieefar N, Masoumi N, Mohseni S, Rezaei N. COVID-19 vaccines mix-and-match: the concept, the efficacy and the doubts. *J Med Virol*. 2022;94(4):1294–1299. doi:10.1002/jmv.27463
8. Troiano G, Nardi A. Vaccine hesitancy in the era of COVID-19. *Public Health*. 2021;194:245–251. doi:10.1016/j.puhe.2021.02.025
9. Joshi A, Kaur M, Kaur R, Grover A, Nash D, El-Mohandes A. Predictors of COVID-19 vaccine acceptance, intention, and hesitancy: a scoping review. *Front Public Heal*. 2021;9:698111. doi:10.3389/fpubh.2021.698111
10. Martora F, Villani A, Marasca C, Fabbrocini G, Potestio L. Skin reaction after SARS-CoV-2 vaccines Reply to “cutaneous adverse reactions following SARS-CoV-2 vaccine booster dose: a real-life multicentre experience”. *J Eur Acad Dermatol Venereol*. 2023;37(1):e43–e44. doi:10.1111/jdv.18531
11. Potestio L, Fabbrocini G, D’Agostino M, Piscitelli I, Martora F. Cutaneous reactions following COVID-19 vaccination: the evidence says “less fear”. *J Cosmet Dermatol*. 2023;22(1):28–29. doi:10.1111/jocd.15533



12. Potestio L, Villani A, Fabbrocini G, Martora F. Cutaneous reactions following booster dose of COVID-19 mRNA vaccination: what we should know? *J Cosmet Dermatol*. 2022;21(11):5339–5340. doi:10.1111/jocd.15331
13. Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. *Clin Microbiol Infect*. 2022;28(2):202–221. doi:10.1016/j.cmi.2021.10.005
14. De Lucia M, Potestio L, Costanzo L, Fabbrocini G, Gallo L. Scabies outbreak during COVID-19: an Italian experience. *Int J Dermatol*. 2021;60(10):1307–1308. doi:10.1111/ijd.15809
15. Martora F, Fabbrocini G, Marasca C. Pityriasis rosea after Moderna mRNA-1273 vaccine: a case series. *Dermatol Ther*. 2022;35(2):e15225. doi:10.1111/dth.15225
16. Megna M, Camela E, Villani A, Tajani A, Fabbrocini G, Potestio L. Tele dermatology: a useful tool also after COVID-19 era? *J Cosmet Dermatol*. 2022;21(6):2309–2310. doi:10.1111/jocd.14938
17. Maronese CA, Caproni M, Moltrasio C, et al. Bullous pemphigoid associated with COVID-19 vaccines: an Italian multicentre study. *Front Med*. 2022;9:841506. doi:10.3389/fmed.2022.841506
18. Martora F, Picone V, Fornaro L, Fabbrocini G, Marasca C. Can COVID-19 cause atypical forms of pityriasis rosea refractory to conventional therapies? *J Med Virol*. 2022;94(4):1292–1293. doi:10.1002/jmv.27535
19. Marzano AV, Maronese CA, Genovese G, et al. Urticarial vasculitis: clinical and laboratory findings with a particular emphasis on differential diagnosis. *J Allergy Clin Immunol*. 2022;149(4):1137–1149. doi:10.1016/j.jaci.2022.02.007
20. Maronese CA, Zelin E, Avallone G, et al. Cutaneous vasculitis and vasculopathy in the era of COVID-19 pandemic. *Front Med*. 2022;9:996288. doi:10.3389/fmed.2022.996288
21. Martora F, Villani A, Battista T, Fabbrocini G, Potestio L. COVID-19 vaccination and inflammatory skin diseases. *J Cosmet Dermatol*. 2023;22(1):32–33. doi:10.1111/jocd.15414
22. Wack S, Patton T, Ferris LK. COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: review of available evidence. *J Am Acad Dermatol*. 2021;85(5):1274–1284. doi:10.1016/j.jaad.2021.07.054
23. Martora F, Battista T, Marasca C, Genco L, Fabbrocini G, Potestio L. Cutaneous reactions following COVID-19 vaccination: a review of the current literature. *Clin Cosmet Investig Dermatol*. 2022;15:2369–2382. doi:10.2147/CCID.S388245
24. van Dam CS, Lede I, Schaar J, Al-Dulaimy M, Rösken R, Smits M. Herpes zoster after COVID vaccination. *Int J Infect Dis*. 2021;111:169–171. doi:10.1016/j.ijid.2021.08.048
25. Akpandak I, Miller DC, Sun Y, Arnold BF, Kelly JD, Acharya NR. Assessment of herpes zoster risk among recipients of COVID-19 vaccine. *JAMA Netw open*. 2022;5(11):e2242240. doi:10.1001/jamanetworkopen.2022.42240
26. Eid E, Abdullah L, Kurban M, Abbas O. Herpes zoster emergence following mRNA COVID-19 vaccine. *J Med Virol*. 2021;93(9):5231–5232. doi:10.1002/jmv.27036
27. Patil A, Goldust M, Wollina U. Herpes zoster: a review of clinical manifestations and management. *Viruses*. 2022;14(2). doi:10.3390/v14020192
28. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71. doi:10.1136/bmj.n71
29. Florea A, Wu J, Qian L, et al. Risk of herpes zoster following mRNA COVID-19 vaccine administration. *Expert Rev Vaccines*. 2023;22(1):643–649. doi:10.1080/14760584.2023.2232451
30. Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. *N Engl J Med*. 2021;385(12):1078–1090. doi:10.1056/NEJMoa2110475
31. Monastirli A, Pasmatzis E, Badavanis G, Panagiotopoulou G, Apostolidou A, Tsambaos D. Herpes Zoster after mRNA COVID-19 vaccination: a case series. *Skinmed*. 2022;20(4):284–288.
32. Psychogiou M, Samarkos M, Mikos N, Hatzakis A. Reactivation of varicella zoster virus after vaccination for SARS-CoV-2. *Vaccines*. 2021;9(6):572. doi:10.3390/vaccines9060572
33. Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. *Ann Rheum Dis*. 2021;80(10):1330–1338. doi:10.1136/annrheumdis-2021-220647
34. Rodríguez-Jiménez P, Chicharro P, Cabrera LM, et al. Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: report of 5 cases. *JAAD Case Rep*. 2021;12:58–59. doi:10.1016/j.jdc.2021.04.014
35. Alpalhão M, Filipe P. Herpes Zoster following SARS-CoV-2 vaccination - A series of four cases. *J Eur Acad Dermatol Venereol*. 2021;35(11):e750–e752. doi:10.1111/jdv.17555
36. Chiu HH, Wei KC, Chen A, Wang WH. Herpes zoster following COVID-19 vaccine: a report of three cases. *QJM*. 2021;114(7):531–532. doi:10.1093/qjmed/hcab208
37. Jiang ZH, Wong LS, Lee CH, Hsu TJ, Yu YH. Disseminated and localised herpes zoster following Oxford-AstraZeneca COVID-19 vaccination. *Indian J Dermatol Venereol Leprol*. 2022;88(3):445. doi:10.25259/IJDVL\_819\_2021
38. Lazzaro DR, Ramachandran R, Cohen E, Galetta SL. Covid-19 vaccination and possible link to Herpes zoster. *Am J Ophthalmol Case Rep*. 2022;25:101359. doi:10.1016/j.ajoc.2022.101359
39. Mohta A, Arora A, Srinivasa R, Mehta RD. Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria being treated with cyclosporine-A report of 3 cases. *J Cosmet Dermatol*. 2021;20(11):3384–3386. doi:10.1111/jocd.14437
40. Vastarella M, Picone V, Martora F, Fabbrocini G. Herpes zoster after ChAdOx1 nCoV-19 vaccine: a case series. *J Eur Acad Dermatol Venereol*. 2021;35(12):e845–e846. doi:10.1111/jdv.17576
41. Birabaharan M, Kaelber DC, Karris MY. Risk of herpes zoster reactivation after messenger RNA COVID-19 vaccination: a cohort study. *J Am Acad Dermatol*. 2022;87(3):649–651. doi:10.1016/j.jaad.2021.11.025
42. Özdemir AK, Kayhan S, Çakmak SK. Herpes zoster after inactivated SARS-CoV-2 vaccine in two healthy young adults. *J Eur Acad Dermatol Venereol*. 2021;35(12):e846–e847. doi:10.1111/jdv.17577
43. Palanivel JA. Herpes zoster after COVID-19 vaccination-Can the vaccine reactivate latent zoster virus? *J Cosmet Dermatol*. 2021;20(11):3376–3377. doi:10.1111/jocd.14470
44. Rehman O, Arya SK, Jha UP, Nayyar S, Goel I. Herpes zoster ophthalmicus after COVID-19 vaccination: chance occurrence or more? *Cornea*. 2022;41(2):254–256. doi:10.1097/ICO.0000000000002881

45. Toscani I, Troiani A, Citterio C, Rocca G, Cavanna L. Herpes zoster following COVID-19 vaccination in long-term breast cancer survivors. *Cureus*. 2021;13(10):e18418. doi:10.7759/cureus.18418
46. Aksu SB, Öztürk GZ. A rare case of shingles after COVID-19 vaccine: is it a possible adverse effect? *Clin Exp Vaccine Res*. 2021;10(2):198–201. doi:10.7774/cevr.2021.10.2.198
47. Ardalan M, Moslemi H, Shafiei S, Tabrizi R, Moselimi M. Herpes-like skin lesion after AstraZeneca vaccination for COVID-19: a case report. *Clin Case Rep*. 2021;9(10):e04883. doi:10.1002/ccr3.4883
48. Channa L, Torre K, Rothe M. Herpes zoster reactivation after mRNA-1273 (Moderna) SARS-CoV-2 vaccination. *JAAD Case Rep*. 2021;15:60–61. doi:10.1016/j.jdc.2021.05.042
49. David E, Landriscina A. Herpes Zoster following COVID-19 vaccination. *J Drugs Dermatol*. 2021;20(8):898–900. doi:10.36849/JDD.6146
50. Tessa I, Kluger N. Ipsilateral herpes zoster after the first dose of BNT162b2 mRNA COVID-19 vaccine. *J Eur Acad Dermatol Venereol*. 2021;35(10):e620–e622. doi:10.1111/jdv.17422
51. Tripathy DM, Kumar S, Saraswat N, Goel S, Ranjan E. Postherpetic granulomatous dermatitis and herpes zoster necroticans triggered by Covid-19 vaccination. *Dermatol Ther*. 2022;35(10):e15707. doi:10.1111/dth.15707
52. Akpandak I, Sechrist SJ, Miller DC, et al. Risk of herpes zoster ophthalmicus after COVID-19 vaccination in a large US healthcare claims database. *Am J Ophthalmol*. 2023. doi:10.1016/j.ajo.2023.07.004
53. Vallianou NG, Tsilingiris D, Karampela I, Liu J, Dalamaga M. Herpes zoster following COVID-19 vaccination in an immunocompetent and vaccinated for herpes zoster adult: a two-vaccine related event? *Metab Open*. 2022;13:100171. doi:10.1016/j.metop.2022.100171
54. You IC, Ahn M, Cho NC. A case report of herpes zoster ophthalmicus and meningitis after COVID-19 vaccination. *J Korean Med Sci*. 2022;37(20):e165. doi:10.3346/jkms.2022.37.e165
55. Català A, Muñoz-Santos C, Galván-Casas C, et al. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. *Br J Dermatol*. 2022;186(1):142–152. doi:10.1111/bjd.20639
56. Fathy RA, McMahon DE, Lee C, et al. Varicella-zoster and herpes simplex virus reactivation post-COVID-19 vaccination: a review of 40 cases in an International Dermatology Registry. *J Eur Acad Dermatol Venereol*. 2022;36(1):e6–e9. doi:10.1111/jdv.17646
57. Naoum C, Hartmann M. Herpes zoster reactivation after COVID-19 vaccination - A retrospective case series of 22 patients. *Int J Dermatol*. 2022;61(5):628–629. doi:10.1111/ijd.16116
58. Lee C, Cotter D, Basa J, Greenberg HL. 20 Post-COVID-19 vaccine-related shingles cases seen at the Las Vegas Dermatology clinic and sent to us via social media. *J Cosmet Dermatol*. 2021;20(7):1960–1964. doi:10.1111/jocd.14210
59. Lee JH, Kim YY, Heo HJ, Park JH, Cho HG, Kim G. Herpes zoster after COVID-19 vaccination, aspect of pain medicine: a retrospective, single-center study. *Anesth pain Med*. 2023;18(1):57–64. doi:10.17085/apm.22207
60. McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. *J Am Acad Dermatol*. 2021;85(1):46–55. doi:10.1016/j.jaad.2021.03.092
61. Ruggiero A, Martora F, Picone V, et al. The impact of COVID-19 infection on patients with psoriasis treated with biologics: an Italian experience. *Clin Exp Dermatol*. 2022;47(12):2280–2282. doi:10.1111/ced.15336
62. Megna M, Potestio L, Battista T, et al. Immune response to Covid-19 mRNA vaccination in psoriasis patients undergoing treatment with biologics. *Clin Exp Dermatol*. 2022;47(12):2310–2312. doi:10.1111/ced.15395
63. Martora F, Martora L, Fabbrocini G, Marasca C. A case of pemphigus vulgaris and hidradenitis suppurativa: may systemic steroids be considered in the standard management of hidradenitis suppurativa? *Ski Appendage Disord*. 2022;8(3):265–268. doi:10.1159/000521712
64. Martora F, Fabbrocini G, Nappa P, Megna M. Impact of the COVID-19 pandemic on hospital admissions of patients with rare diseases: an experience of a Southern Italy referral center. *Int J Dermatol*. 2022;61(7):e237–e238. doi:10.1111/ijd.16236
65. Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. *Expert Opin Drug Saf*. 2023;1–17. doi:10.1080/14740338.2023.2173170
66. Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. *Expert Opin Drug Saf*. 2023;1–16. doi:10.1080/14740338.2023.2173171
67. Martora F, Megna M, Battista T, et al. Adalimumab, ustekinumab, and secukinumab in the management of hidradenitis suppurativa: a review of the real-life experience. *Clin Cosmet Investig Dermatol*. 2023;16:135–148. doi:10.2147/CCID.S391356
68. Napolitano M, Maffei M, Patruno C, et al. Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis. *Dermatol Ther*. 2021;34(6):e15120. doi:10.1111/dth.15120
69. Patruno C, Potestio L, Napolitano M. Clinical phenotypes of adult atopic dermatitis and related therapies. *Curr Opin Allergy Clin Immunol*. 2022;22(4):242–249. doi:10.1097/ACI.0000000000000837
70. Ruggiero A, Potestio L, Cacciapuoti S, et al. Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real-life study. *Dermatol Ther*. 2022;35(12):e15941. doi:10.1111/dth.15941
71. Patruno C, Potestio L, Scalvenzi M, et al. Dupilumab for the treatment of adult atopic dermatitis in special populations. *J Dermatolog Treat*. 2022;1–6. doi:10.1080/09546634.2022.2102121
72. Villani A, Potestio L, Fabbrocini G, Scalvenzi M. New emerging treatment options for advanced basal cell carcinoma and squamous cell carcinoma. *Adv Ther*. 2022;39(3):1164–1178. doi:10.1007/s12325-022-02044-1
73. Ahmed B, Qadir MI, Ghafoor S. Malignant melanoma: skin cancer-diagnosis, prevention, and treatment. *Crit Rev Eukaryot Gene Expr*. 2020;30(4):291–297. doi:10.1615/CritRevEukaryotGeneExpr.2020028454
74. Villani A, Ocampo-Garza SS, Potestio L, et al. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma. *Expert Opin Drug Saf*. 2022;21(1):21–29. doi:10.1080/14740338.2022.1993819
75. Marasca C, Annunziata MC, Camela E, et al. Tele dermatology and inflammatory skin conditions during COVID-19 era: new perspectives and applications. *J Clin Med*. 2022;11(6):1511. doi:10.3390/jcm11061511
76. Roizmann B, Desrosiers RC, Fleckenstein B, Lopez C, Minson AC, Studdert MJ. The family herpesviridae: an update. The Herpesvirus Study Group of the International Committee on Taxonomy of Viruses. *Arch Virol*. 1992;123(3–4):425–449. doi:10.1007/BF01317276
77. Kukhanova MK, Korovina AN, Kochetkov SN. Human herpes simplex virus: life cycle and development of inhibitors. *Biochemistry*. 2014;79(13):1635–1652. doi:10.1134/S0006297914130124



78. Carneiro VC, de S, Pereira JG, de Paula VS. Family Herpesviridae and neuroinfections: current status and research in progress. *Mem Inst Oswaldo Cruz*. 2022;117:e220200. doi:10.1590/0074-02760220200
79. Brambilla L, Maronese CA, Turlaki A, Veraldi S. Herpes zoster following COVID-19: a report of three cases. *Eur J Dermatol*. 2020;30(6):754–756. doi:10.1684/ejd.2020.3924
80. Shafiee A, Amini MJ, Arabzadeh Bahri R, et al. Herpesviruses reactivation following COVID-19 vaccination: a systematic review and meta-analysis. *Eur J Med Res*. 2023;28(1):278. doi:10.1186/s40001-023-01238-9
81. Stoeger T, Adler H. “Novel” triggers of herpesvirus reactivation and their potential health relevance. *Front Microbiol*. 2018;9:3207. doi:10.3389/fmicb.2018.03207
82. Seneff S, Nigh G, Kyriakopoulos AM, McCullough PA. Innate immune suppression by SARS-CoV-2 mRNA vaccinations: the role of G-quadruplexes, exosomes, and MicroRNAs. *Food Chem Toxicol*. 2022;164:113008. doi:10.1016/j.fct.2022.113008
83. Liu J, Wang J, Xu J, et al. Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines. *Cell Discov*. 2021;7(1):99. doi:10.1038/s41421-021-00329-3
84. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. *J Exp Med*. 2005;202(5):637–650. doi:10.1084/jem.20050821
85. Desai HD, Sharma K, Shah A, et al. Can SARS-CoV-2 vaccine increase the risk of reactivation of Varicella zoster? A systematic review. *J Cosmet Dermatol*. 2021;20(11):3350–3361. doi:10.1111/jocd.14521
86. Etace F, Naguib T, Daveluy S. Herpes zoster dermatitis in a COVID-19 vaccinated healthy man after 1 dose of varicella vaccine. *JAAD Case Rep*. 2022;22:102–103. doi:10.1016/j.jder.2021.12.043
87. Megna M, Ruggiero A, Battista T, Marano L, Cacciapuoti S, Potestio L. Long-term efficacy and safety of risankizumab for moderate to severe psoriasis: a 2-year real-life retrospective study. *J Clin Med*. 2023;12(9):3233. doi:10.3390/jcm12093233
88. Megna M, Battista T, Potestio L, et al. A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab. *J Cosmet Dermatol*. 2023;22(3):1146–1148. doi:10.1111/jocd.15543
89. Ruggiero A, Camela E, Potestio L, Fabbrocini G, Megna M. Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. *Expert Opin Drug Saf*. 2022;21(12):1445–1451. doi:10.1080/14740338.2022.2160447
90. Napolitano M, Fabbrocini G, Genco L, Martora F, Potestio L, Patruno C. Rapid improvement in pruritus in atopic dermatitis patients treated with upadacitinib: a real-life experience. *J Eur Acad Dermatol Venereol*. 2022;36(9):1497–1498. doi:10.1111/jdv.18137
91. Picone V, Martora F, Fabbrocini G, Marano L. “Covid arm”: abnormal side effect after Moderna COVID-19 vaccine. *Dermatol Ther*. 2022;35(1):e15197. doi:10.1111/dth.15197
92. Picone V, Fabbrocini G, Martora L, Martora F. A case of new-onset lichen planus after COVID-19 vaccination. *Dermatol Ther*. 2022;12(3):801–805. doi:10.1007/s13555-022-00689-y
93. Camela E, Potestio L, Fabbrocini G, Pallotta S, Megna M. The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs. *Expert Opin Investig Drugs*. 2023;1–16. doi:10.1080/13543784.2023.2219387
94. Camela E, Potestio L, Fabbrocini G, Ruggiero A, Megna M. New frontiers in personalized medicine in psoriasis. *Expert Opin Biol Ther*. 2022;1–3. doi:10.1080/14712598.2022.2113872

## Clinical, Cosmetic and Investigational Dermatology

Dovepress

### Publish your work in this journal

Clinical, Cosmetic and Investigational Dermatology is an international, peer-reviewed, open access, online journal that focuses on the latest clinical and experimental research in all aspects of skin disease and cosmetic interventions. This journal is indexed on CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/clinical-cosmetic-and-investigational-dermatology-journal>